Pharmaceutical Business review

Isomorphic Labs raises $5bn to advance drug pipeline

Isomorphic Labs manages both partnered initiatives and wholly owned drug development programmes. Credit: T. Schneider/Shutterstock.com.

Sequoia Capital and Greenoaks co-led the oversubscribed round, with additional participation from Andreessen Horowitz (a16z) and other new investors. Alphabet maintained its backing with continued investment.

The round also included existing investors CapitalG, GV, MGX, Temasek, Thrive Capital, and the UK Sovereign AI Fund.

The company will use the capital to scale its drug design engine, IsoDDE, and expand its pipeline of drug candidates.

IsoDDE brings together foundational simulation models designed to function across multiple therapeutic areas and drug modalities to identify and refine molecules with drug-like properties.

Isomorphic Labs has reported positive preclinical findings across collaborative projects as well as internal programmes in immunology and oncology, preparing the pipeline for initial clinical testing.

Isomorphic Labs founder and CEO Demis Hassabis said: “When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI. Our drug design engine is generating molecules with unprecedented precision and speed.

“This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programmes towards clinical trials to deliver tangible impact for patients.”

Proceeds from the financing will also fund translational and clinical development infrastructure as drug candidates move towards trials.

In addition, the company is establishing a partner network to improve understanding of mechanistic disease biology, whilst building global infrastructure to support its bioengineering and computational biology operations.

In March 2025, the company raised $600m in its first external funding round as it pushes forward with AI-driven drug discovery.

Exit mobile version